Skip to main navigation Skip to search Skip to main content

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

  • Braude, Michael (Primary Chief Investigator (PCI))
  • Pianko, Stephen (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date8/10/24 → 1/12/26

Clinical Trial Phase

  • Phase III (a & b)